Walgreens Boots Alliance, Inc. or Mesoblast Limited: Who Manages SG&A Costs Better?

SG&A Cost Management: Walgreens vs. Mesoblast

__timestampMesoblast LimitedWalgreens Boots Alliance, Inc.
Wednesday, January 1, 20145417000017992000000
Thursday, January 1, 20156537800022400000000
Friday, January 1, 20165226300023910000000
Sunday, January 1, 20173507200023813000000
Monday, January 1, 20182741500024694000000
Tuesday, January 1, 20193698300023557000000
Wednesday, January 1, 20205091800025436000000
Friday, January 1, 20216358600024586000000
Saturday, January 1, 20225796700027295000000
Sunday, January 1, 20235310700034205000000
Monday, January 1, 20242362600028113000000
Loading chart...

Unlocking the unknown

Walgreens Boots Alliance vs. Mesoblast: A Tale of SG&A Management

In the competitive world of business, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Walgreens Boots Alliance, Inc. and Mesoblast Limited, two giants in their respective fields, offer a fascinating study in contrasts. From 2014 to 2024, Walgreens consistently reported SG&A expenses that were over 400 times higher than Mesoblast's, reflecting its vast scale and global operations. However, Mesoblast showed a commendable reduction in SG&A costs by approximately 56% from 2015 to 2024, indicating a strategic tightening of its financial belt. Meanwhile, Walgreens saw a steady increase, peaking in 2024. This data highlights the different financial strategies employed by a healthcare retail giant and a biotechnology firm. As businesses navigate economic challenges, understanding these strategies offers valuable insights into effective cost management.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025